Catalyst Event

Biogen Inc (BIIB) · Other

From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)

3/25/2026, 12:00:00 AM

OtherSentiment: Positive

Announced an exclusive license agreement with Alteogen on March 25, 2026, to develop subcutaneous formulations for two products. The deal includes a $20 million upfront payment and up to $549 million in potential milestones plus royalties. This event is estimated to have a low impact given the relatively small upfront payment.

Korean Translation

2026년 3월 25일, 알테오젠과 2개 제품에 대한 피하 제형 개발을 위한 독점 라이선스 계약을 발표함. 계약금 2,000만 달러와 최대 5억 4,900만 달러의 마일스톤 및 로열티를 포함함. 계약금 규모가 작아 낮은 영향이 예상됨.

Related Recent Events

View Full Timeline